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Abstract
Background: There is debate in the literature as to whether inclusion of a placebo arm
may alter characteristics of antidepressant trials. However, previous research has fo-
cused on response rates of various antidepressants on average only, ignoring potential
differences among drugs or other aspects of trial findings. Little is known about the
impact of a placebo arm on all-cause dropout and dropout due to adverse events.
Methods: We carried out a systematic review of published and unpublished double-blind
randomized controlled trials (RCTs) for the acute treatment of unipolar major depression
(update: January 2016). The probability of being allocated to placebo (p) was the exposure of
interest, and we examined its influence on responders (efficacy), all-cause dropouts (accept-
ability) and dropouts due to adverse events (tolerability), while accounting for differences in
drugs, trials and patient characteristics in multivariate random effects meta-regression.
Results: We included 421 studies (68 305 participants) comparing 16 antidepressants or
placebo; p ranged from 20% to 50%. Response rate was lower [risk ratio (RR) 0.87; 95%
confidence interval (CI) 0.83, 0.92] and all-cause dropout rate higher (RR 1.19; 95% CI
1.08, 1.31) for the same antidepressants in placebo-controlled trials compared with
head-to-head trials. The probability of responding decreased by 3% (95% CI 2–5%) for
every 10% increase in p, whereas the risk of all-cause dropout increased by 4% (95% CI
1–7%). Tolerability was unaffected by p. Response rate was inversely correlated with
dropouts due to any cause (correlation coefficient 0.48; 95% CI 0.58, 0.36) and due
to adverse events (0.34; 95% CI 0.44, 0.23).
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Conclusions: For the same antidepressant, response rate was on average smaller and
dropouts higher when placebo was included; however, no association was found with
dropouts due to adverse events. Decreased patient expectations, larger dropout rates
and use of inappropriate statistical methods to impute missing data may explain this
phenomenon. The findings call for caution in the integration of randomized evidence
involving placebo arms.
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Background
The expectations and preferences patients may have re-
garding a treatment can influence their response to that
treatment. In open trials, patients who are allocated to the
non-preferred treatment may experience ‘resentful demor-
alization’ and consequently show lower adherence to the
assigned treatment.1 In major depression, strong expecta-
tions of improvement were associated with both a higher
probability of complete response and reduced severity of
depression at the end of a multi-arm trial of psychotherapy
and pharmacotherapy.2 A trial including a preference arm
showed that in mild-to-moderate depression, taking into
account patients’ preferences for pharmacotherapy or
psychotherapy was associated with additional benefit.3
Although many instruments have been developed to assess
patient expectations, measurement is complex and the va-
lidity and reliability of different approaches are unclear.4
The role of placebo in randomized controlled trials
(RCTs) has been long debated from both methodological
and ethical perspectives.5 Although a standard requirement
for licensing approval in regulatory settings, the use of pla-
cebo in phase III studies has been challenged.6 In the field
of depression it has been suggested that placebo arms are
needed because equivalence between a new drug and stan-
dard treatment is not evidence of efficacy unless the new
drug is also more effective than placebo.7 However, the
high rate of placebo responders in antidepressant trials has
added a layer of complexity to the process of designing
trials and interpreting results.8 Trial participants are in-
formed that they will receive either one of several active
treatments, or placebo, with the probability of placebo
ranging from 0% in a head-to-head trial to 50% in a two-
arm placebo-controlled trial. Several studies have shown
that administration of a placebo that simulates an active
Key messages
• Previous reviews found that in antidepressant trials, response to active intervention gradually decreased among
head-to-head studies, multi-arm placebo-controlled studies and two-arm placebo-controlled studies, in this order.
However, these studies did not adjust their results for differences in trial or patient characteristics and, more impor-
tantly, they did not account for differences between individual drugs and investigated the impact of the inclusion of
placebo on response rate only.
• By synthesizing 706 active treatment arms, using appropriate multivariate meta-regression techniques, our study is
the largest to date to provide evidence on the impact of inclusion of placebo arm on the response to 16 different
antidepressants and also on the likelihood of dropout due to any cause and due to adverse events.
• This study found that therapeutic response to the same antidepressant arm was on average smaller and dropouts
more likely when the probability of receiving placebo increased. By contrast, there was no influence on dropout rate
due to adverse events.
• For the same drug and the same probability of receiving placebo, larger dropout rates were associated with lower re-
sponse rates to the treatment.
• The probability of receiving placebo in the clinical trial alters the characteristics of the trial by inducing different
response and dropout rates with the same antidepressants among its participants.
• Decreased patient expectations in placebo-controlled trials and the widespread use of the ‘last observation carried
forward’ approach to record missing outcome data might explain this phenomenon. The probability of receiving
placebo should be considered when interpreting and synthesizing results from randomized controlled trials in major
depression.
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treatment can mimic the effects of the pharmacological in-
tervention, depending on contextual factors and mediated
through psychological and neurobiological mechanisms
(‘the powerful placebo’).9 Conversely, in blinded clinical
trials the knowledge that an inactive treatment might be re-
ceived could reduce the response to an active treatment,
and abolish the placebo response. Patient expectations
could also be responsible for high rates of adverse events,
even in patients who do not receive an active treatment
(‘the nocebo phenomenon’).10
Many factors can be associated with placebo response in
antidepressant trials, such as baseline severity,11 dosing
schedule12 and length of trial.13 However, the inclusion of a
placebo arm is an important issue not only from a clinical
viewpoint, but also from a methodological one, because it
can introduce heterogeneity between trials and violate the
assumptions underlying meta-analyses.14 Two previous
studies investigated this issue. Papakostas and Fava studied
182 placebo-controlled trials and found that a higher proba-
bility of receiving placebo reduced the response to the active
intervention.15 Sinyor and colleagues16 synthesized 90 head-
to-head and placebo-controlled trials and found that re-
sponse to active intervention gradually decreased between
head-to-head studies, multi-arm placebo-controlled studies
and two-arm placebo-controlled studies. However, these
studies did not include a large sample of trials, they focused
only on efficacy, did not adjust results for differences in trial
or patient characteristics16 and did not account for the dif-
ferent drugs used in the trials.15,16 Additionally, as publica-
tion bias is a well-known threat in antidepressant trials, it is
not known how this might have affected the conclusions of
previous studies. Therefore to properly address this ques-
tion, we conducted a systematic review and meta-regression
analysis including unpublished data, and examined not only
whether the probability of receiving placebo modifies re-
sponse to treatment but also whether it affects acceptability
and tolerability in antidepressant trials.
Methods
This study is based on a systematic review and network
meta-analysis of the comparative efficacy and acceptability
of first-generation and second-generation antidepressants
in the acute treatment of major depression.17 The protocol
was registered in PROSPERO (CRD42012002291) and
published.18 The results are reported according to the
Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA) guidelines. Eligible trials were
identified from seven electronic databases (CENTRAL,
CINAHL, EMBASE, LiLACS, MEDLINE, MEDLINE In-
Process and PSYCINFO) from inception to 8 January
2016. The reference lists of relevant papers were also
scrutinized. Files of the national drug licensing agencies in
six countries (USA, UK, The Netherlands, Sweden, Japan
and Australia), the European Medicines Agency and sev-
eral trial registries were searched for published, unpub-
lished and ongoing RCTs (for further details on the search
strategy, see reference18).
Inclusion and exclusion criteria
The following criteria had to be satisfied for studies to be
eligible for the meta-analysis and meta-regression analysis:
(i) randomized controlled trials (RCTs) reported as double-
blind, comparing one active drug with another or with
placebo in the acute phase treatment of major depression
(studies where sequence generation was not clearly
random, or where the allocation was clearly not concealed,
were excluded); (ii) patients aged 18 years or older, of both
sexes, with a primary diagnosis of non-psychotic, unipolar
major depression, according to any standard diagnostic
criteria (DSM, Feighner or ICD-10 criteria), with no serious
concomitant medical illness; and (iii) any second-generation
antidepressant (agomelatine, bupropion, citalopram, desven-
lafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine,
levomilnacipran, milnacipran, mirtazapine, nefazodone, par-
oxetine, reboxetine, sertraline, trazodone, venlafaxine, vilazo-
done and vortioxetine) and two first-generation drugs
included in the WHO list of essential medicines (amitriptyline,
clomipramine). Full details about inclusion and exclusion cri-
teria are reported in the published protocol, with full details
about the rationale for selecting the investigational drugs.18
Data extraction and risk of bias
Two persons independently reviewed the titles and abstracts
retrieved by the search. The full text of potentially eligible
articles was obtained, and any disagreements about eligibil-
ity were resolved via discussion with a third reviewer. The
structured data extraction sheet covered the study and par-
ticipant characteristics, intervention details and outcome
measures. Severity scores at baseline were transformed
to Hamilton Depression Rating Scale (17-item) scores
when necessary (Supplementary Appendix 1, available as
Supplementary data at IJE online). The results for response
reported in the original publication were compared
with those in any unpublished study reports, and a
decision tree was used for data extraction (Supplementary
Appendix 1, available as Supplementary data at IJE on-
line).18 Where necessary, authors were contacted in order to
obtain further information. Two independent raters assessed
generation of allocation sequence, allocation concealment,
blinding of study personnel and participants, blinding of out-
come assessor and other domains, including sponsorship
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using the Cochrane risk of bias tool. Inter-rater agreement
on risk of bias judgements was assessed in a sample of the
eligible articles. Analyses of completers only or of last
observations carried forward (LOCF) were considered at
high risk of attrition bias. Studies supported by industry
were considered at high risk of sponsorship bias, and
arms of drugs manufactured by the sponsor of the trial were -
considered to be at higher risk of bias than comparator arms
(see Supplementary Appendix 1, available as Supplementary
data at IJE online for more details).
Outcomes and exposure
The outcome for efficacy was response rate, defined as the
percentage of patients who had a reduction of at least 50%
on the total score between baseline and week 8 on a stan-
dardized observer-rating scale for depression (e.g. Hamilton
Depression Rating Scale or Montgomery-A˚sberg Depression
Rating Scale). When only changes in scores were reported,
we imputed responder rates using a standardized method.19
Dropout due to any cause and dropout due to adverse
events were also recorded.
The exposure of interest was the probability of being al-
located to placebo, denoted as p and estimated using equal
allocation ratios. We analysed p as a dichotomous variable
as p¼ 0% or p> 0% (arms from head-to-head versus
placebo-controlled trials), as a trichotomous variable
(p¼ 0%, 0%>p< 50%, p¼50% corresponding to arms
from head-to-head trials, placebo-controlled trials with
more than two active arms and two-arm placebo-controlled
trials) and as a continuous variable (the number of placebo
arms over the number of all study arms).
Statistical analysis
The preliminary analysis aimed to identify trial and patient
characteristics that differed between active arms with
p¼ 0% and p> 0% (Supplementary Appendix 2, available
as Supplementary data at IJE online). We used random-
effects meta-regression with each characteristic as the de-
pendent variable and dichotomous p as covariate.20 If a
precision measure of the characteristic was not available or
relevant, we employed a conventional regression analysis.
The characteristics associated with p in this analysis were
considered potential confounders of the association be-
tween p and study outcomes. In the main analysis, we fit
multivariable multivariate random-effects meta-regression
models for the log-transformed response and dropout with
p¼ 0%, 0%>p> 50% and p¼ 50% and by entering p as a
continuous exposure variable (Supplementary Appendix 2,
available as Supplementary data at IJE online).21 We con-
trolled for possible confounding by drug by including it as
a covariate. We entered other potential confounders into
the model to evaluate their independent impact on re-
sponse and dropout. We fit the final models for each out-
come by including the exposure variable p, the drugs and
the trial or patient characteristics that were independent
predictors of response and dropout.
In a sensitivity analysis we excluded arms of amitripty-
line and trazodone, which are difficult to blind due to side
effects. We also re-ran the main analysis models using the
logit-transformed responses and dropout. To explore the as-
sociation between dropout and response rates, we estimated
overall correlation coefficients using a random-effects
model.22 We also ran a multivariate meta-analysis of log-
transformed response rates using the dropout rate as covari-
ate (on top of placebo and active drugs). Heterogeneity was
measured using the random-effects standard deviation s.
Statistical analyses were performed in Stata version 13.1
and R version 3.0.2.23,24 For full details about the statistical
models, see Supplementary Appendix 2, available as
Supplementary data at IJE online.
Results
A total of 28 541 citations were reviewed (Supplementary
Appendix 5, available as Supplementary data at IJE on-
line). We included 421 studies (68 305 participants) 73 of
which are unpublished (Supplementary Appendix 1, avail-
able as Supplementary data at IJE online): in total, 706
arms of active drugs that were examined both in 169 head-
to-head trials (n¼ 29 841) and in 252 placebo-controlled
studies (n¼ 38 464) (see Supplementary Appendix 4, avail-
able as Supplementary data at IJE online for reference list
of included studies). The 706 arms studied 16 different
antidepressants. About half of the active drug arms (340)
belonged to 169 studies with 0% probability of receiving
placebo (p). The placebo-controlled studies had two to five
arms, so that p ranged between 20% and 50%.
Supplementary Appendix 6 (available as Supplementary
data at IJE online) shows the distribution of the arms in
the various types of studies with and without placebo.
Studies with p¼ 0% were comparable to those with a 20%
or higher probability of placebo in terms of year of publi-
cation, use of rescue medication, risk of bias and frequency
of reporting response and all-cause dropout rates
(Table 1). Most head-to-head studies included only two
arms (158 studies, 93.5%) whereas many placebo-
controlled trials had three arms or more (197, 78.2%). The
response rate was available in 386 studies and 650 arms
(92.1%). The dropout rate was reported in 378 studies and
644 arms (91.2%), and dropout for adverse events in 354
studies and 596 arms (84.4%). Placebo-controlled trials
were more likely to report dropouts for adverse events.
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The risk of bias was unclear in most placebo-controlled
and head-to-head trials. Outcome assessors were reported
to be blinded more often in head-to-head studies than in
placebo-controlled trials (Table 1). In a sample of 155
articles, inter-rater agreement on risk of bias judgements
ranged from 89% to 98.1% (Supplementary Appendix 1,
available as Supplementary data at IJE online).
The arms from head-to-head trials and from placebo-
controlled trials were similar in terms of mean age, base-
line severity score of participants, use of LOCF approach
and sample size (Table 2). The mean percentage of female
participants was higher in arms with zero probability of
receiving placebo. Most trial arms were at high risk of
attrition bias, both in placebo-controlled and in
head-to-head trials. Appropriate imputation of missing
data was more frequent in arms from placebo-controlled
trials than arms from head-to-head studies. Head-to-head
studies were more frequently sponsored by industry.
However, active arms were more likely to be associated
with the sponsor of the trial in a placebo-controlled trial
than in a head-to-head study (Table 2).
For all drugs except amitriptyline, the mean response rate
was higher in the head-to-head trials compared with the
placebo-controlled trials (Figure 1a). For most drugs
there was a negative association with the probability of
receiving placebo. The lowest mean response was
Table 1. Characteristics of the included studies. P-values are obtained from random-effect meta-regressions or simple regres-
sions as described in the Supplementary Appendix, available as Supplementary data at IJE online (see Supplementary
Appendix 1, available as Supplementary data at IJE online, for the definition of the covariates)
Trials Studies with p¼0%
(head-to-head trials)
(n¼169, 100%)a
Studies with p between 20%
and 50% (placebo-controlled
trials)(n¼252, 100%)a
P-value
Median year of study completion [range] 1999 1999.5 0.71
[1980, 2015] [1978, 2014]
Use of rescue medication 66 (39.1%) 76 (30.2%) 0.06
Use of placebo run-in phase 71 (42.0%) 148 (58.7%) 0.001
No. of arms
2 158 (93.5%) 55 (21.8%) <0.001
3 9 (5.3%) 142 (56.3%)
>3 2 (1.2%) 55 (21.8%)
Risk of bias
Generation of random sequence 0.41
Low risk of bias 30 (17.8%) 53 (21.0%)
Unclear risk of bias 139 (82.2%) 199 (79.0%)
Concealment of allocation 0.18
Low risk of bias 19 (11.2%) 40 (15.9%)
Unclear risk of bias 150 (88.8%) 212 (84.1%)
Blinding of assessors 0.04
Stated but not tested 34 (20.1%) 32 (12.7%)
Unclear risk of bias 135 (79.9%) 220 (87.3%)
Response rates available 154 (91.1%) 232 (92.1%) 0.73
Unpublished report available and presents ade-
quate response data
50 (29.6%) 121 (48.0%) <0.001
Response rate presented in published report 128 (83.1%) 163 (70.3%) 0.005
Published and unpublished reports on response
are in agreement
139 (90.3%) 197 (84.9%) 0.126
All-cause dropout reported 153 (90.5%) 225 (89.3%) 0.68
Response and all-cause dropout reported 141 (83.4%) 213 (84.5%) 0.76
Dropout for adverse events reported 134 (79.3%) 220 (87.3%) 0.03
Funding <0.001
High risk of sponsorship bias (Industry
funding or unclear)
159 (94.0%) 205 (81.3%)
Low risk of sponsorship bias (not-for profit
funding or no funding)
10 (6.0%) 47 (18.7%)
p: probability of receiving placebo.
aPercentages are calculated out of the total number of trials reporting on response (154 and 232, respectively).
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observed in two-arm placebo-controlled trials (p¼ 50%), a
higher response in multi-arm placebo-controlled trials
(20%p< 50%) and the highest response in head-to-head
studies (p¼ 0%). Conversely, all-cause dropout rates were
lower in head-to-head studies (Figure 1b). For several drugs
(citalopram, escitalopram, mirtazapine, nefazodone and par-
oxetine) there was a positive association between p and
dropout from all causes. By contrast, for dropout due to ad-
verse events no clear pattern emerged (Suppplementary
Appendix 7, available as Supplementary data at IJE online).
The probability of response to an active drug decreased
by 13% (RR 0.87, 95% CI 0.83 to 0.92) if the drug was
tested in a placebo-controlled trial rather than in a head-
to-head trial (Table 3). There was also a monotonic associ-
ation between response and the number of arms in
placebo-controlled trials. The probability of response de-
creased by 16% when p¼ 50% (RR 0.84, 95% CI 0.77,
0.92) and 12% (RR 0.88, 95% CI 0.83, 0.93) when
20%p< 50% compared with p¼ 0%. It decreased by
3% (RR 0.97, 95% CI 0.95, 0.98) for every 10% increase
in the probability of being allocated to placebo.
The risk of dropout increased by 19% (RR 1.19, 95%
CI 1.08, 1.31) when the arm was part of a placebo-
controlled trial rather than a head-to-head study (Table 3).
This risk increased by 4% (RR 1.04, 95% CI 1.01, 1.07)
for every 10% increase in the probability of being allocated
to placebo. No important differences were found for drop-
out for adverse events. The results are presented graphi-
cally in Supplementary Appendix 8, available as
Supplementary data at IJE online.
Table 2. Characteristics of the included arms. P-values are obtained from random-effect meta-regressions or simple regressions
as described in the Supplementary Appendix, available as Supplementary data at IJE online (see Supplementary Appendix 1,
available as Supplementary data at IJE online for the definition of the covariates).
Active arms Arms from studies with
p¼0%(n¼340, 100%)
Arms from studies with
p between 20% and
50%(n¼366, 100%)
P-value
Mean age (from 496 arms) 44.5 43.1 0.34
Mean percentage of females (from 332 arms) 64.8 61.2 0.007
Mean baseline depression score (from 637 arms) 24.4 24.3 0.24
Mean sample size 88 104 0.27
Attrition bias
Low risk of bias (appropriate imputations or
dropout <1%)
7 (2.1%) 43 (11.7%) <0.001
High risk of bias (incomplete data analysis) 77 (22.6%) 59 (16.1%)
High risk of bias (LOCF approach) 227 (66.8%) 239 (65.3%)
Unclear risk of bias 29 (8.5%) 25 (6.8%)
High risk of sponsorship bias (the industry
funding the trial manufactures the drug
examined in the arm)
186 (54.7%) 270 (73.8%) 0.001
Active intervention in the arm**
Agomelatine 9 (2.6%) 17 (4.6%) 0.94
Amitriptyline 46 (13.5%) 26 (7.1%) <0.001
Bupropion 7 (2.1%) 18 (4.9%) 0.44
Citalopram 20 (5.9%) 16 (4.4%) 0.01
Duloxetine 7 (2.1%) 28 (7.7%) 0.05
Escitalopram 23 (6.8%) 22 (6.0%) 0.02
Fluoxetine 63 (18.5%) 44 (12.0%) 0.08
Fluvoxamine 13 (3.8%) 12 (3.3%) <0.001
Mirtazapine 18 (5.3%) 17 (4.6%) 0.04
Nefazodone 7 (2.1%) 8 (2.2%) 0.42
Paroxetine 51 (15.0%) 56 (15.3%) 0.005
Reboxetine 5 (1.5%) 10 (2.7%) 0.87
Sertaline 24 (7.1%) 25 (6.8%) 0.04
Trazodone 13 (3.8%) 9 (2.5%) 0.02
Venlafaxine 33 (9.7%) 33 (9.0%) 0.01
Vortioxetine 1 (0.3%) 25 (6.8%) 0.001
p, probability of receiving placebo; LOCF, last observation carried forward.
**P-values are obtained from X2 tests.
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After excluding amitriptyline and trazodone in the sen-
sitivity analysis, the differences between arms from
placebo-controlled and head-to-head trials became slightly
more pronounced (Table 2 in Supplementary Appendix 3,
available as Supplementary data at IJE online). Re-analysis
of the data using the logit-transformed response and drop-
out rates led to similar results (Table 3 in Supplementary
Appendix 3, available as Supplementary data at IJE on-
line). Response rate was inversely correlated with dropout
rate: the summary correlation coefficient was 0.48 (95%
CI 0.58, 0.36) (Supplementary Appendix 9, available
as Supplementary data at IJE online). The correlation be-
tween the two outcomes was not affected by the probabil-
ity of receiving placebo.
(a)
(b)
Probability of recieving placebo Π=50%
Probability of recieving placebo 20%≥Π<50%
Probability of recieving placebo Π=0%
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Figure 1. Response to treatment (1a) and dropout rate for any reason (1b) as estimated in active arms grouped by probability of receiving placebo.
Drugs are ordered by response and dropout rates estimated in the head-to-head trials (p¼ 0%). The bars and confidence intervals for ALL (all drugs)
are estimated from the multivariate model after adjusting for differences between active drugs. AGOM, agomelatine; AMIT, amitriptyline; BUPR,
bupropion; CITA, citalopram; DULO, duloxetine; ESCI, escitalopram; FLUO, fluoxetine; FLUV, fluvoxamine; LEVO, levomilnacipran; MILN, milnaci-
pran; MIRT, mirtazapine; NEFA, nefazodone; PARO, paroxetine; REBO, reboxetine; SERT, sertraline; TRAZ, trazodone; VENL, venlafaxine; VORT, vorti-
oxetine. The raw percentages are shown in Table 1 in Supplementary Appendix 3, available as Supplementary data at IJE online.
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We added the variables that had different distributions
in placebo-controlled and head-to-head studies (sponsor-
ship, blinding and attrition bias, availability of the unpub-
lished report and the use of a placebo run-in phase) in a
multivariate model. The percentage of female participants
was not associated with response or all-cause dropout (for
a 10% increase in the percentage of female participants,
we obtained RR for response: 1.01 95% CI (0.98, 1.04)
and RR for dropout 0.99 (95% CI 0.94, 1.04) and was
omitted from the multivariate analysis in order to increase
the sample size (374 arms had missing values). Only the
availability of an unpublished report and the use of pla-
cebo run-in phase had an independent effect on response
or dropout (Table 4 in Supplementary Appendix 3, avail-
able as Supplementary data at IJE online). The probability
of receiving placebo remained the most important predic-
tor of response and dropout after including the two varia-
bles in the model (Table 5 in Supplemementary Appendix
3, available as Supplementary data at IJE online).
Studies with higher dropout rates showed lower average
response rates (Figure 2). In the multivariate random-effects
meta-analysis adjusted for drug differences and the inclusion
of placebo, the coefficient between log-transformed re-
sponse rate and dropout rate for any cause was 0.17 (95%
CI 0.22, 0.13). This means that, for the same drug,
an arm with a 10% dropout rate will have a 31% greater
response rate compared with an arm with a 50% dropout
rate. The correlation between log-transformed response
rate and dropout rate due to adverse events was a bit
smaller than that for dropout for any cause (0.34, 95% CI
Table 3. Results from multivariate meta-regression for the impact of placebo-controlled trials in response and dropout with ac-
tive antidepressant drugs. Results are adjusted for the type of antidepressant. Heterogeneity standard deviations did not differ
materially across models (less than 1% change) and were s¼ 0.20 (response), s¼ 0.36 (all-cause dropout), s¼0.43 (dropout due
to adverse events)
Response to active treatment All-cause dropout Dropout due to adverse events
Number of active arms (studies) 647 (386) 641 (378) 580 (350)
Risk ratios (95% CI): p ¼ 0% 1 1 1
p >0% 0.87 (0.83, 0.92) 1.19 (1.08, 1.31) 1.07 (0.94, 1.23)
p ¼ 0% 1 1 1
20%p<50% 0.88 (0.83, 0.93) 1.19 (1.08, 1.31) 0.98 (0.78, 1.22)
p ¼ 50% 0.84 (0.77, 0.92) 1.15 (0.99, 1.34) 1.08 (0.94, 1.25)
for p increase by 10% 0.97 (0.95, 0.98) 1.04 (1.01, 1.07) 1.06 (0.73, 1.56)
p, probability of being allocated to placebo arm.
Figure 2. Response rate in active arms versus dropout rate due to any cause. Data in blue are from arms with probability of receiving placebo p> 0%
and data in black are from arms with probability of receiving placebo p¼ 0%. The red line corresponds to the multivariate regression line
(exponentiated).
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0.44, 0.23) (Supplementary Appendix 10, available as
Supplementary data at IJE online).
Discussion
In this large meta-epidemiological study, we found that the
therapeutic response to antidepressants was on average
smaller and dropouts were more likely when a placebo arm
was included in a trial. For the same drug and the same
probability of receiving placebo, greater dropout rates from
all causes were associated with a smaller response to the
treatment. Of note, dropout rates due to adverse events
were not related to the probability of receiving placebo.
There are several explanations for the association between
placebo arms, response rates and dropout observed in this
study. First, patient expectations may influence the response
to a treatment independently of the efficacy of the drug.25
This unspecific, contextual response to treatment might be
greater in patients enrolled in head-to-head trials, who know
that they will receive an active drug, than in patients enrolled
in placebo-controlled trials (Supplementary Appendix 11,
available as Supplementary data at IJE online). The overall,
absolute response to the drug observed in the study will con-
sequently be larger in a head-to-head trial than in a placebo-
controlled trial, even if the specific effect of the drug remains
the same. Note that the contextual response can be measured
in a placebo-controlled study (as the response to placebo) but
not in a head-to-head study. The impact of differential con-
textual response might be amplified by patient differences; it
is possible that patients recruited in placebo-controlled trials
differ from those recruited in head-to-head studies in their at-
titude and pre-onceptions about psychopharmacological
treatments. Interestingly, no association of response or drop-
out rates with the probability of receiving placebo was
observed for amitriptyline and trazodone, possibly because
the side effects made blinding difficult.
Second, the LOCF approach to imputing missing out-
come data may have affected estimates of treatment
responses.26 In our study, more patients randomized to an
active drug in a placebo-controlled trial dropped out than
patients enrolled in a head-to-head trial of the same drug.
Carrying their poor early response forward will result in
estimates of response that are biased downwards, resulting
in underestimation of the absolute response to active drugs
in placebo-controlled studies. In our study, a high dropout
rate was associated with poor response independently of
the presence of a placebo arm. The use of LOCF may thus
act jointly with patient expectations to produce the greater
response in head-to-head studies. As only 9% of the
included studies (46 studies) used appropriate methods to
impute missing outcome data (multiple imputations or
mixed-effect model repeated measure) examining only
newer drugs, a sensitivity analysis using only those studies
would not be very informative.
A third explanation for the larger response rates in the
head-to-head trials could be biases in conduct, analysis or
reporting of these trials, driven by commercial interests.27
This seems unlikely because funding by industry was not
associated with important differences in response or drop-
out rates, in line with our previous analysis of new-
generation antidepressants.28 Furthermore, our literature
search was comprehensive, and we included a substantial
amount of unpublished data, including data from drug
companies and licensing authorities, which are known to
show smaller effects of antidepressants than published
trials.18
Dropout due to any cause includes dropout due to inef-
ficacy; this might explain why dropout in active arms in
placebo-controlled studies is larger than dropout in active-
controlled studies. As with response, the knowledge that
there is a probability of being allocated to the placebo arm
impacts on patients’ improvement in symptoms and on
their decision to leave the trial. In contrast, adverse events
(such as nausea, sexual dysfunction or weight gain) are the
direct results of the pharmacological substances and hence
unlikely to be influenced by patient expectations. This can
explain why dropouts due to adverse events are not modi-
fied by the presence of a placebo arm in trials.
This study is based on the largest systematic collection
of published and unpublished antidepressant trials ever
compiled.17 Our analysis is the first to account for differen-
ces between the studied antidepressants and several patient
and trial characteristics via multivariate meta-regression.
However, our study has some limitations. The meta-
regression analyses provide observational evidence that
might be subject to residual confounding, or confounding
by variables not included in our analyses. We did not have
access to individual patient data and could not test our hy-
pothesis that differences in response are due to the LOCF
approach. Finally, we used the total number of arms in a
trial to estimate the probability of receiving placebo by as-
suming equal randomization ratios in all study arms, ig-
noring other randomization ratios.
Our findings have potentially important implications for
the evaluation of antidepressants. The Food and Drug
Administration (FDA) issued guidelines for the evaluation
of antidepressants, which have not been updated since
1977.29 According to these guidelines, five different types of
controls may be used in a clinical trial: (i) placebo concur-
rent control; (ii) dose-comparison concurrent control;
(iii) no-treatment concurrent control; (iv) active-treatment
concurrent control; and (v) historical control. A clear prefer-
ence is, however, given to placebo-controlled studies over
active-control trials: ‘. . .because alternative study designs,
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especially active-control studies, may not be informative, ex-
posing subjects to risk but without being able to collect use-
ful information’.29 Our study supports the notion that in the
case of antidepressants, comparative effectiveness research
may not only be more relevant for clinical and reimburse-
ment decisions,30 but also may be less biased than placebo-
controlled trials research. In the case of antidepressants, we
need phase III, superiority trials with an active comparator,
chosen among the most effective and better-tolerated treat-
ments on the market.6
In conclusion, a higher probability of receiving placebo
in a randomized trial increased the chances of dropout and
decreased the absolute response of patients to active anti-
depressants. This might be explained by decreased patient
expectations and the use of the LOCF approach in combi-
nation with larger dropout rates in placebo-controlled tri-
als. The synthesis of placebo-controlled and head-to-head
trials in meta-analyses is common practice. Our study sug-
gests that the strength of association between probability
of receiving placebo and response might be different across
the 16 drugs examined. This means that not only the
response to the drug but also the relative differences in re-
sponse between drugs is influenced by the probability of
receiving placebo. Consequently, careful attention is
needed when results from studies with different probabili-
ties of receiving placebo are combined to estimate relative
treatment effects. Future research should replicate our
analysis in other areas of health care, especially in areas
where response to placebo and patient expectations are
important, for example in pain research.
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